MolecularMD receives patent for detecting drug resistant EGFR mutant

MolecularMD has exclusively licensed the commercial rights to this property which covers methods for detecting the EGFR T790M mutation.

The new patent describes methods of detecting the EGFR T790M mutation as it relates to acquired resistance in patients harboring activating EGFR mutations.

Monitoring for the emergence of the EGFR T790M mutation will allow for early identification of acquired resistance and prompt treatment intervention.

MolecularMD Chief Scientific Officer Stephane Wong said that high proportion of non-small cell lung cancer (NSCLC) patients treated with erlotinib or gefitinib develop the gatekeeper EGFR T790M mutation